Data-backed drug development and care delivery company Emyria Limited (ASX: EMD) has selected world leading pharmaceutical products testing to lead an extensive compound screening programme for the unique MDMA-analogue library.
The analysis plan developed with Eurofins will provide the University of Western Australia (UWA) and Emyria insights to inform lead compound identification and further development.
Emyria’s Managing Director, Dr Michael Winlo, said the data received will also strengthen the intellectual property portfolio for the library.
We are pleased to be working with global leader, Eurofins to screen our first batch of novel MDMA-analogues after successfully completing purity and stability testing at UWA,” Dr Winlo said.
“Eurofins are experts in supporting a complete drug development cycle for new chemical entities and they routinely work with the largest and most innovative biopharmaceutical companies in the world. The analysis we have prepared will help Emyria select the most promising drug candidates within the MDMA analogue library for further preclinical evaluation and development.”
The MDMA analogy library
Emyria recently secured exclusive rights to a library of more than 100 novel MDMA analogues from the University of Western Australia creating a unique drug-discovery pipeline.
The library of compounds has been compiled by the highly regarded research group led by medicinal chemist, Dr Matt Piggott, who has been working with MDMA analogues and exploring their therapeutic potential, for more than 10 years.
Emyria aims to screen and expand the existing library in order to identify families of patentable compounds with the greatest promise as new psychedelic-assisted therapies and treatments for other neurological disorders.
Alongside screening, Emyria is leading a global patent strategy, already underway, as well as further clinical development and commercialisation of this unexplored research space.
The programme has the potential to result in the commercialisation of multiple, novel, CNS-active compounds to help treat patients with major unmet needs.